MedTrace Logo

Probiotic in Infant Growth, Allergy and Immunity Study

NCT06412042 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-14

No results posted yet for this study

Summary

To evaluate the intervention effects of Bifidobacterium animalis subsp. lactis strain BLa80 in promoting growth and development (including gut microbiota and physical growth and development) of healthy infants and young children across different age groups, enhancing immune function, improving allergy incidence, and analyzing the safety of BLa80 in relation to infant growth and development, allergy incidence, and gut microbiota.

Conditions

  • Healthy
  • Infant ALL

Interventions

DIETARY_SUPPLEMENT

Probiotic BLa80

Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.

OTHER

Placebo Maltodextrin

Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.

Sponsors & Collaborators

  • Wecare Probiotics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Natalina Soesilawati, Dr. · Karya Medika II Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
36 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-15
Primary Completion
2024-09-15
Completion
2024-09-25

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412042 on ClinicalTrials.gov